Jasmine Zain, MD, Highlights Current & Upcoming T-Cell Lymphomas Treatments

Michael Jordan, MD, Differentiates HLH Treatment in Pediatric Patients Versus Adults with Emapalumab

Germ Cell Tumors Have the Potential to Become Leukemia

What Are Next Steps for Retrotope's RT001?

What Makes RT001 Unique?

How FDA’s Breakthrough Therapy Designation Program Changed the Rare Disease Space

Rare Tumor Patient Engagement Network: Getting Patients Involved in Cancer Research

Fibrolamellar Cancer Foundation President on What’s Next for Rare Cancers

Addressing Diagnosis Challenges in the Rare Disease Space

AI: The Future for Rare Disease Treatments

Humility- "The Best Characteristic in Medicine"

Using Genomic Technology to Stratify Pediatric Cancer Patients

FDA Approves First Chemotherapy-Free Treatment for Waldenstrom's Macroglobulinemia

Understanding Genetics to Develop Future Treatments for Rare Cancers

Pediatric MDS Update with Dr. Inga Hofmann Zhang

MDS/AML Overlap and Novel Therapies with Dr. Naval Daver

PNH Treatment Update

MDS/MPN Overlap Syndromes and Myelofibrosis

Treating Children with Aplastic Anemia

Challenges for Treating Patients with Rare Cancers

Molecular Events—Not Time—Define Pediatric Oncology Outcomes

Disparities Between Pediatric and Adult Cancers

Uncovering Rare Genetic Factors with Multiplex Germline Testing

Back to the Drawing Board: The Pivotal Role of Clinical Trials in Lymphoma Treatments

A Family Affair: Multiplex Germline Testing in Melanoma

Advantages of Brentuximab Vedotin and Chemotherapy Combination for Advanced Stage Hodgkin Lymphoma

Efficacy of Ibrutinib and Rituximab Combination for Waldenström's Macroglobulinemia

Benefits of CART-T Therapies to Treat Rare Cancers

Providing Pediatric Cancer Patients With Tools to Boost Resiliency During Treatment

Brain Tumors and Team Approaches